The Full Circle: 360 News Report 07.04.08 Happy 232nd birthday United States of America.In this Fourth of July spectacular edition of The Full Circle we're closing out the week with our own brand of Microsoft inspired fireworks.
We've got news about the upcoming Microsoft price...
FOCUS AstraZeneca faces 'big risk' of a delay to its next major drug on FDA vote On Wednesday night, the U.S.Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 14 to 2 that diabetes drugs should go through long-term heart risk tests -- even those that have shown no heart...
Halozyme Therapeutics Bladder Cancer Drug Chemophase Meets Study Goals (FinancialWire) Halozyme Therapeutics Inc.(NASDAQ: HALO) said that its Chemophase drug candidate met safety and tolerability goals in an early-to-midstage study.
Chemophase is being studied as a possible bladder cancer treatment....
Halozyme Therapeutics Bladder Cancer Drug Chemophase Meets Study Goals (FinancialWire) Halozyme Therapeutics Inc.(NASDAQ: HALO) said that its Chemophase drug candidate met safety and tolerability goals in an early-to-midstage study.
Chemophase is being studied as a possible bladder cancer treatment....
New test to detect breast cancer 70% of women who develop breast cancer may have no identifiable risk factors other than age.A new FDA approved test may change that by picking up precancerous cells years before cancer can be detected on a mammogram.
49 year old Karen...
[external] Health Winners & Losers: Halozyme Health stocks traded Tuesday on a variety of business and regulatory news.The Nasdaq and Amex biotechnology indices hopped 1.7% and 1.4%, respectively.
They outdid the Amex pharmaceutical index, which registered a 0.8% rise, more in...
Joining Forces: Highlights from The Power of Partnerships Be the first to rate this article: Please Sign in to rate this.The recently released book The Power of Partnership, a joint project between ASAE & The Center and the U.S.
Chamber of Commerce, details how partnerships enable...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial - Product appears safe with no dose-limiting toxicities - - Chemophase dose for pivotal trials successfully determined - - Halozyme to seek input from regulatory authorities in order to advance into pivotal clinical program in 2009 - SAN...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its...
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial SAN DIEGO, June 30 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced a status update for its...
Full Circle News Report It might be the longest Full Circle to date and we're talking a bunch of Gears of War 2 news, something doesn't add up with Alone in the Dark, Denis Dyack of Silicon Knights gets overly defensive about Too Human, Microsoft winning the battle...
The Full Circle: 360 News Report 06.27.08 It might be the longest Full Circle to date and we're talking a bunch of Gears of War 2 news, something doesn't add up with Alone in the Dark, Denis Dyack of Silicon Knights gets overly defensive about Too Human, Microsoft winning the battle...
Boston, MA -- Form4Oracle: Insider Trading Report: Halozyme Therapeutics Inc (HALO) As the stock was trading at less than 50 percent of its 52-week high, Kirk Randal J, Director at Halozyme Therapeutics Inc (HALO) has reported buying $1.39M today.Over the last four weeks Kirk Randal J, Director has bought $3.17M...
BioImagene Launches AgilityBio, a New Generation Contract Research Organization Leveraging Its Innovative Digi - BioImagene, a leading provider of innovative digital pathology solutions for preclinical research and cancer diagnosis, launched AgilityBio an integrated contract research organization (CRO).AgilityBio offers preclinical and clinical...
BioImagene Launches AgilityBio, a New Generation Contract Research Organization Leveraging Its Innovative Digi BioImagene Launches AgilityBio, a New Generation Contract Research Organization Leveraging Its Innovative Digital Pathology System CUPERTINO, Calif.--(BUSINESS WIRE)--Jun 23, 2008 - BioImagene, a leading provider of innovative digital...
BioImagene Launches AgilityBio, a New Generation Contract Research Organization Leveraging Its Innovative Digi , 8:30 AM EST News source: Business Wire BioImagene, a leading provider of innovative digital pathology solutions for preclinical research and cancer diagnosis, launched AgilityBio -- an integrated contract research organization (CRO).
Early Esophageal Cancer and Pre-Cancer Eliminated With Non-Surgical Treatment Combination SUNNYVALE, Calif., May 20 PRNewswire BARRX Medical, Inc., a global technology leader in treating Barrett's esophagus, today announced the publication of two related European trials which report a 100% eradication rate for early esophageal...
Teliris Announces Telepresence Installs for Seven Additional Global 2000 Companies var addthis_pub = 'gary7pick'; Teliris News LAS VEGAS The new Teliris Telepresence rooms will meet the demands of four new companies and three current customers that are adding fourth and fifth rounds of Teliris Telepresence rooms.New...
Teliris Announces Telepresence Installs for Seven Additional Global 2000 Companies LAS VEGAS, June 18 /PRNewswire/ -- InfoComm 2008 -- Teliris (http://www.teliris.com), the leading provider of immersive telepresence solutions, reaffirmed today its continuing lead in paying customer deployments by announcing seven...
Teliris Announces Telepresence Installs for Seven Additional Global 2000 Companies New Customers Include New York Stock Exchange, Aviva, Philip Morris and British American Tobacco LAS VEGAS, June 18 /PRNewswire/ -- InfoComm 2008 -- Teliris (www.teliris.com), the leading provider of immersive telepresence solutions,...
Teliris Announces Telepresence Installs for Seven Additional Global 2000 Companies LAS VEGAS, June 18 /PRNewswire/ -- - New Customers Include New York Stock Exchange, Aviva, Philip Morris and British American Tobacco InfoComm 2008 -- Teliris (www.teliris.com), the leading provider of immersive telepresence solutions,...
Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.(Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at...
